Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss

NCT07446998 · Recruiting

Last updated 2026-05-28

This clinical trial is testing whether the drug enobosarm, when used alongside semaglutide, can help people with obesity or overweight lose more weight compared to using semaglutide alone.

Status Recruiting Currently enrolling participants.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 200 people Planned (estimated).

Who can join Ages 65–100 · all sexes

Timeline Started 2026-03 · est. completion 2027-12

Where 10 sites · United States

What this study is testing ClinicalTrials.gov NCT07446998 ↗

Description as written by the study sponsor.

The primary objective of this study is to assess the effect of enobosarm on total body weight

Treatments tested

Enobosarm Drug

Enobosarm is an oral, new chemical entity class, SARM, that has demonstrated tissue-selective, dose-dependent improvement in body composition with increases in muscle mass and reduces fat mass, improves insulin resistance, has no masculinizing effects in women, has neutral prostate effects in men, and no increases in hematocrit. Increases in muscle mass have resulted in improvements in muscle strength and physical function.
Semaglutide (Wegovy) weekly injection Drug

Semaglutide for Chronic Weight Management

Main thing measured	To determine the effect of enobosarm in combination with semaglutide on total body weight compared to semaglutide alone.
Sponsor	Veru Inc.
Conditions studied	Obesity & Overweight, Mobility Disability, HOMA-IR
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07446998 ↗